Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets

D Kugel, G Kochs, K Obojes, J Roth… - Journal of …, 2009 - Am Soc Microbiol
D Kugel, G Kochs, K Obojes, J Roth, GP Kobinger, D Kobasa, O Haller, P Staeheli…
Journal of virology, 2009Am Soc Microbiol
The type I interferon (IFN) response represents one of the first lines of defense against
influenza virus infections. In this study, we assessed the protective potential of exogenous
IFN-α against seasonal and highly pathogenic influenza viruses in ferrets. Intranasal
treatment with IFN-α several hours before infection with the H1N1 influenza A virus strain
A/USSR/90/77 reduced viral titers in nasal washes at least 100-fold compared to mock-
treated controls. IFN-treated animals developed only mild and transient respiratory …
Abstract
The type I interferon (IFN) response represents one of the first lines of defense against influenza virus infections. In this study, we assessed the protective potential of exogenous IFN-α against seasonal and highly pathogenic influenza viruses in ferrets. Intranasal treatment with IFN-α several hours before infection with the H1N1 influenza A virus strain A/USSR/90/77 reduced viral titers in nasal washes at least 100-fold compared to mock-treated controls. IFN-treated animals developed only mild and transient respiratory symptoms, and the characteristic fever peak seen in mock-treated ferrets 2 days after infection was not observed. Repeated application of IFN-α substantially increased the protective effect of the cytokine treatment. IFN-α did not increase survival after infection with the highly pathogenic H5N1 avian influenza A virus strain A/Vietnam/1203/2004. However, viral titers in nasal washes were significantly reduced at days 1 and 3 postinfection. Our study shows that intranasal application of IFN-α can protect ferrets from seasonal influenza viruses, which replicate mainly in the upper respiratory tract, but not from highly pathogenic influenza viruses, which also disseminate to the lung. Based on these results, a more intensive evaluation of IFN-α as an emergency drug against pandemic influenza A is warranted.
American Society for Microbiology